Blockchain Registration Transaction Record

Helus Pharma Raises $50M in Public Offering to Advance Mental Health Pipeline

Helus Pharma closes $50M public offering to fund Phase 3 trials for HLP003 in major depressive disorder and Phase 2 for HLP004 in anxiety. Learn about the company's NSA pipeline.

This news matters because Helus Pharma is developing innovative treatments for major depressive disorder and generalized anxiety disorder, conditions that affect millions worldwide. The $50 million funding will accelerate clinical trials for HLP003 and HLP004, potentially bringing new, more effective therapies to patients who have not responded to existing treatments. With Breakthrough Therapy Designation for HLP003, the company is positioned to address a significant unmet need in mental health, offering hope for durable improvements in neuroplasticity and symptom relief.